FDA will review Daiichi Sankyo, Lilly drug Prasugrel for heart attack

Daiichi Sankyo Company, Limited (TSE: 4568), and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome who are managed with PCI. – Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) confirmed that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February_3, 2009.

Prasugrel cuts risk of stent-related clots

Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel. Reductions seen as soon as three days and out to 450 days in patients who received either bare metal or drug-eluting stents. – The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statistically significant reduction in the risk of coronary stent thrombosis (ST) – a major concern for physicians and patients with potentially fatal consequences – in patients who received a stent as compared to standard therapy with clopidogrel (Plavix) plus aspirin, according to a stent analysis from the head-to-head TRITON-TIMI 38 trial.

27% lower mortality in top hospitals, finds HealthGrades

Hospital quality gap persists, resulting in 171,424 preventable deaths, according to HealthGrades’ Sixth Annual Hospital Quality and Clinical Excellence study. – Patients treated at top-rated hospitals in US are nearly one-third less likely to die, on average, than those admitted to all other hospitals, according to a study released by HealthGrades (Nasdaq: HGRD), the leading independent healthcare ratings organization.